The Oslo Medicines Initiative:
a new social contract with pharma
15 June 2021
Continuing our successful online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
The Oslo Medicines Initiative: Better access to effective, novel, high-priced medicines – a new vision for collaboration between the public and private sectors is a new initiative of the WHO Regional Office for Europe, developed together with the Norwegian Ministry of Health and Care Services and the Norwegian Medicines Agency.
The Initiative aims to provide a neutral platform for the public and private sectors to jointly outline a vision for equitable and sustainable access to effective, innovative and affordable medicines.
Join us to discuss why a new social contract is needed to build an environment of mutual trust and cooperation between the pharmaceutical industry, governments and patients.
Dr Natasha Azzopardi-Muscat
Director of the Division of Country Health Policies and Systems, WHO European Region
Dr Audun Haga
Director General, Norwegian Medicines Agency
Jo de Cock
CEO, National Institute of Health and Disability Insurance (NIHDI), Belgium
EPHA’s series of online discussions on key access to medicines (A2M) priorities brings together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.